Company intelligence / Profile preview

Parkure

Motherwell / Glasgow*, Scotland, United Kingdomuk.linkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Parkure focuses on early-stage discovery and preclinical development of small molecule drugs to halt neurodegeneration in Parkinson’s disease. Their approach leverages genetically engineered fruit flies to rapidly screen compounds. Lead candidates are in preclinical or IND-enabling stages; no clinical trial results reported yet.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

PR-002

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Contracts with third-party pharmaceutical companies for compound testing using their fly-based screening approach.

Beyond the preview

Go deeper on Parkure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parkure.

Explore the full profile